Are Analyst Upgrades Signaling a Turning Point in Charles River’s (CRL) Biopharma Pipeline Narrative?
Analyst upgrades for Charles River Laboratories International (CRL) from Morgan Stanley and CLSA indicate a more positive outlook due to stronger biopharma funding and a supportive regulatory environment in China. This shift contrasts with recent concerns regarding softer organic revenue and weaker returns, suggesting that momentum and regulatory tailwinds could reshape expectations for the company's future work pipeline. While the upgrades provide a brighter long-term view, Charles River's near-term guidance still projects a revenue decline, emphasizing that the positive trends must translate into improved bookings to materialize fully.
Are Analyst Upgrades Signaling a Turning Point in Charles River’s (CRL) Biopharma Pipeline Narrative?
Charles River Laboratories International (CRL) recently received analyst upgrades from Morgan Stanley and CLSA, driven by improving biopharma funding and a more supportive regulatory environment in China. These upgrades suggest a potential turning point for the company, contrasting with recent concerns about softer revenue and weaker returns. While the long-term outlook appears more positive, CRL's near-term guidance still indicates a challenging top line.
MEDP - Medpace Holdings Inc Latest SEC Filings
This article provides the latest SEC filings information for Medpace Holdings Inc (MEDP), along with comprehensive financial data, key performance indicators, and company statistics. It details various financial ratios, insider and institutional ownership, profitability margins, and stock performance metrics for the company.
Why is Morgan Stanley Bullish on Charles River Laboratories International, Inc. (CRL) as a Top Stock to Buy According to Ariel Investment?
Morgan Stanley recently upgraded Charles River Laboratories International, Inc. (CRL) to Overweight, raising its price target to $220 due to strong biopharma funding and the company's leading preclinical capabilities. The investment bank anticipates upside from acquisitions and divestitures, as well as increased safety testing activity. CLSA also upgraded CRL to Outperform, citing a more favorable regulatory environment in China.
Law firm investigates Charles River Labs officers for possible breach of fiduciary duties to shareholders
Halper Sadeh LLC is investigating whether officers and directors of Charles River Laboratories International, Inc. breached their fiduciary duties to shareholders. Long-term shareholders may be eligible for corporate governance reforms, financial incentives, or other relief. The firm encourages shareholders to contact them promptly to enforce their rights, aiming for improved company transparency and accountability.
CRL - Charles River Laboratories International Inc Latest SEC Filings
This article provides a detailed financial overview and recent SEC filing information for Charles River Laboratories International Inc (CRL). It covers key financial metrics, stock performance data, analyst ratings, and details on insider and institutional ownership, offering a comprehensive snapshot of the company's current market position.
Did Charles River Laboratories International, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, has initiated an investigation into whether officers and directors of Charles River Laboratories International, Inc. (CRL) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss potential legal actions, such as corporate governance reforms or the return of funds to the company, emphasizing the importance of shareholder involvement in promoting corporate transparency and accountability.
Charles River Laboratories International Non-Executive Director James Foster Sells 27% Of Holding
James Foster, a Non-Executive Director at Charles River Laboratories International, recently sold US$17 million worth of company stock, reducing his total holding by 27%. This sale, executed at US$225 per share, is the largest insider sale for the company in the last year. Despite this, insiders still own a significant 1.1% of the company, valued at US$125 million, which generally incentivizes long-term growth.
Charles River Laboratories International Non-Executive Director James Foster Sells 27% Of Holding
James Foster, a Non-Executive Director at Charles River Laboratories International, recently sold US$17 million worth of company stock, reducing his total holding by 27%. This sale, though substantial, is notable as the largest insider sale in the past year, even at a share price below current levels. Despite this insider selling, the company still boasts 1.1% insider ownership, valued at US$125 million, which generally aligns management interests with shareholders, though the selling activity suggests caution.
Charles River Labs faces a thin catalyst day. Focus stays on earnings and cash flow.
Charles River Labs is currently trading without any new company-specific catalysts, shifting the focus to its underlying business model, U.S. listing, and upcoming earnings report. The company's core business revolves around contract research and development services, making its revenue sensitive to biotech and pharmaceutical spending cycles. For investors, the company's earnings timing, margin trends, and free cash flow are more significant than short-term stock movements.
Charles River Laboratories International Stock 7-Day Winning Spree: Stock Climbs 26%
Charles River Laboratories International (CRL) has experienced a 7-day winning streak, with its stock climbing 26% and its market cap increasing by about $2.3 billion to $11 billion. Despite this recent surge, the article raises concerns about the company's weak operating performance, poor financial condition, and high valuation, suggesting the stock might be unattractive. It emphasizes the importance of predictive signals over notifications for identifying future winning stocks.
Charles River Laboratories International (CRL) On Lilly TuneLab Deal And The Valuation Debate
Charles River Laboratories International (CRL) has garnered attention for its collaboration with Lilly TuneLab, an AI-powered drug discovery platform by Eli Lilly. This partnership, which involves Charles River providing nonclinical testing services, contributes to a recent stock rally, prompting a valuation debate. While some perceive CRL as undervalued based on a narrative-driven fair value, a contrasting DCF analysis suggests it is overvalued.
Charles River Laboratories International (CRL) On Lilly TuneLab Deal And The Valuation Debate
Charles River Laboratories International (CRL) has partnered with Lilly TuneLab, an AI drug discovery platform, to provide nonclinical testing services, leading to a significant rally in its stock price. The article discusses varied valuations for CRL, with Simply Wall St's popular narrative suggesting a 27% undervaluation at $313.61, partly due to a strategic acquisition of a non-human primate supplier. Conversely, a DCF model from the same source indicates the stock might be overvalued at its current price of $229.09, suggesting a fair value of $76.49.
Form 4 Charles River Laboratories Intl For: 1 July By Investing.com
This article announces a Form 4 filing for Charles River Laboratories International, submitted on July 1st. It also includes general market updates and lists current financial data for various indices, commodities, and stocks. The content provides a snapshot of market performance without elaborating on the details of the Form 4 filing itself.
Charles River Labs director James C Foster reduces stake by $16.8m
James C. Foster, a director at Charles River Laboratories International, Inc. (NASDAQ:CRL), sold 75,000 shares of common stock for $16.8 million at $225.00 per share, executed under a Rule 10b5-1 trading plan. This sale occurred while the stock was trading near its 52-week high and has delivered a 47% return over the past year, though InvestingPro analysis suggests it is currently overvalued. Foster retains significant indirect ownership through various trusts.
Director at Charles River (NYSE: CRL) sells 75K shares under 10b5-1 plan
Charles River Laboratories director James C. Foster sold 75,000 shares of common stock at $225.00 per share, totaling $16.88 million. This transaction was conducted under a pre-arranged Rule 10b5-1 Trading Plan adopted on March 6, 2026. Following the sale, Foster directly holds 31,596 shares and maintains significant indirect holdings through various trusts and GRATs.
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Charles River Laboratories International Inc. (CRL) stock gained 1.01% on Wednesday, closing at $229.09,
Charles River Laboratories updates operations strategy as research demand evolves
Charles River Laboratories is refining its operations strategy to meet the increasing demand for outsourced preclinical research and development. The company provides a comprehensive suite of services, from discovery through nonclinical development, emphasizing operational efficiency and integrated offerings for biotech and pharmaceutical clients globally. This strategy helps clients streamline drug discovery and development processes by offering specialized scientific capabilities and standardized, scalable services.
Charles River Laboratories stock hits 52-week high at 229.18 USD
Charles River Laboratories International Inc. (CRL) stock has reached a new 52-week high at $229.18 USD, with its market capitalization now at $11 billion. This surge reflects a 43.93% increase over the past year, with recent upgrades by Morgan Stanley and CLSA, and a raised price target by Argus, further boosting investor confidence. The company's expansion of its AI-enabled digital pathology platform also contributes to its positive outlook and strategic growth.
Charles River Laboratories stock hits 52-week high at 229.18 USD By Investing.com
Charles River Laboratories International Inc. (CRL) stock has reached a new 52-week high of $229.18, with a market capitalization of $11 billion and a 43.93% increase over the past year. This surge follows upgrades from Morgan Stanley and CLSA, citing increased biopharma funding and a favorable regulatory environment. The company's expansion of its AI-enabled digital pathology platform and strategic mergers also contribute to its strong performance and future growth prospects.
Charles River Laboratories stock hits 52-week high at 229.18 USD
Charles River Laboratories International Inc. (CRL) stock has reached a new 52-week high of $229.18, driven by strong investor confidence and recent positive developments. The company's stock surged over 12% in the past week and 43.93% over the last year, reflecting robust performance despite being potentially overvalued according to InvestingPro's Fair Value analysis. This milestone follows upgrades from Morgan Stanley and CLSA, an increased price target from Argus, and the expansion of its AI-enabled digital pathology platform.
Is This the Right Time to Hold CRL Stock in Your Portfolio?
Charles River Laboratories International, Inc. (CRL) is positioned for growth due to its Research Models and Services (RMS) business and CRADL adoption, along with strategic deals and a solid financial standing. However, soft biopharma demand and adverse currency fluctuations could impact its results. The company has outperformed its industry and the S&P 500, with a strong earnings yield and consistent earnings surprises.
CRL (CRL) Form 144: 75,000-share resale via UBS Financial Services
Charles River Laboratories International, Inc. (CRL) filed a Form 144 showing a proposed resale of 75,000 shares of common stock through UBS Financial Services, with an aggregate offering price of $16,875,000.00. The filing also indicated 48,167,730 shares outstanding as of June 29, 2026, and detailed several RSU/PSU lots with various grant and vesting dates contributing to the shares being sold. This notice is a statutory requirement for affiliates planning to sell restricted or control securities.
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Shares of Charles River Laboratories International Inc. (CRL) rose 4.55% to $225.57 on Monday, marking its fifth consecutive day of gains. This strong performance occurred during a positive trading session for the broader stock market, with the S&P 500 Index and Dow Jones Industrial Average also seeing gains.
Charles River Laboratories strategy focus, S&P 500 health stock in contract research
Charles River Laboratories is a key US health-sector contract research provider listed on the NYSE and part of the S&P 500 index. The company specializes in preclinical and clinical contract research services, helping pharmaceutical and biotech firms outsource essential development steps, particularly in early-stage research and animal models for drug development. Its strategy focuses on being a full-service partner, leveraging structural outsourcing trends to achieve scale efficiencies and maintain strong client relationships.
Price to earnings forward of Charles River Laboratories International, Inc. – NYSE:CRL
This page displays the price-to-earnings forward ratio for Charles River Laboratories International, Inc. (NYSE: CRL). It indicates that the market was closed with no trades recorded at the time of viewing. The content is primarily a financial data point within a larger financial information platform.
Enterprise value to revenue forward of Charles River Laboratories International, Inc. – NYSE:CRL
This article focuses on the enterprise value to revenue forward metric for Charles River Laboratories International, Inc. (NYSE: CRL). It emphasizes financial analysis tools offered by TradingView and mentions various data partners. The content primarily highlights financial data and analytical resources for the company's stock.
Enterprise value to revenue forward of Charles River Laboratories International, Inc. – DUS:RV6
The article provides financial information for Charles River Laboratories International, Inc. (DUS:RV6), specifically focusing on its enterprise value to revenue forward. It appears to be a financial data page from TradingView, displaying key metrics for the company. The page indicates the market is closed with no trades.
OP Asset Management Ltd Takes Position in Howmet Aerospace Inc. $HWM
OP Asset Management Ltd has initiated a new position in Howmet Aerospace Inc. (NYSE:HWM) by purchasing 38,642 shares valued at approximately $8.9 million in the first quarter. Analysts maintain a bullish outlook on the stock, with a consensus "Moderate Buy" rating and an average price target of $287.53, following strong quarterly results and raised guidance for FY 2026. The company also declared a quarterly dividend, and several other hedge funds have recently adjusted their stakes in Howmet Aerospace.
Enterprise value to EBIT forward of Charles River Laboratories International, Inc. – NYSE:CRL
The article serves as a financial data point for Charles River Laboratories International, Inc. (NYSE: CRL), specifically highlighting its enterprise value to EBIT forward metric on TradingView. It provides contextual navigation for investors seeking financial information on this stock.
Enterprise value to EBIT forward of Charles River Laboratories International, Inc. – MUN:RV6
This article provides the enterprise value to EBIT forward for Charles River Laboratories International, Inc. (MUN:RV6) on the TradingView platform. It highlights that the market was closed and there were no trades. The content is primarily a data page from TradingView, offering financial information for Charles River Laboratories International.
RV6 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Charles River Laboratories International, Inc. (RV6) stock, including price targets and analyst ratings. It details financial information, such as past earnings and revenue, future estimates, and the company's EBITDA, while also answering frequently asked questions about the stock.
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors despite daily gains
Shares of Charles River Laboratories International Inc. (CRL) rose 1.43% to $215.75 on Friday, marking its fourth consecutive day of gains. However, despite this daily increase, the stock underperformed compared to its competitors as the broader market, represented by the S&P 500 Index and Dow Jones Industrial Average, experienced slight declines.
Visa Inc. $V Position Lowered by Amiral Gestion
Amiral Gestion significantly reduced its stake in Visa Inc. by 45% during the first quarter of 2026, selling 33,755 shares and retaining 41,255 shares valued at $12.5 million. Despite this reduction, Visa's recent financial performance has been strong, with EPS and revenue beating estimates, along with a $20 billion share buyback authorization and a $0.67 quarterly dividend. Analysts maintain an overall "Buy" rating with an average target price of $387.78, indicating continued confidence in the company's long-term prospects.
Charles River Laboratories analyst calls stay supportive, shares with a clear Wall Street consensus
Despite a recent guidance trim, Charles River Laboratories (CRL) maintains a clear positive consensus among Wall Street analysts, with 9 out of 12 ratings being "Buy." Analysts acknowledge the mixed near-term outlook but remain constructive due to improving biopharma funding trends and strong demand for preclinical services, with Morgan Stanley upgrading the stock to Overweight. The average price target suggests an upside from current trading levels, indicating continued confidence in its long-term potential in contract research services.
Enterprise value to revenue forward of Charles River Laboratories International, Inc. – MUN:RV6
This article provides the enterprise value to revenue forward for Charles River Laboratories International, Inc. (MUN:RV6). The content emphasizes financial data available on TradingView, specifically under the "Financials" section for the Munich Stock Exchange listing. It is a data point aimed at investors tracking the company's valuation metrics.
Charles River Laboratories International Inc (CRL) Stock Up 5.2% but GF Value Says Overvalued -- GF Score: 70/100
Charles River Laboratories International Inc (CRL) saw its stock rise by 5.2% to $212.71, but GuruFocus's GF Value™ suggests it is 9.3% overvalued with an estimated fair value of $194.70. The company holds a GF Score™ of 70/100, indicating above-average quality and performance, with strong profitability but low growth. No insider transactions have been reported in the last three months, suggesting a cautious stance from insiders.
Charles River Laboratories International, Inc. Actuals & Estimates (NYSE:CRL)
This article provides an overview of Charles River Laboratories International, Inc. (NYSE: CRL), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights the company's recent stock price increases, analyst predictions for its future price, and detailed financial actuals and estimates. The article also provides information on the company's earnings, revenue, market capitalization, and employee count.
CRL Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Charles River Laboratories International, Inc. (CRL) stock, based on analyst opinions. It includes current stock performance metrics, historical highs and lows, financial data like earnings and revenue, and discusses the company's market capitalization and volatility. The content also addresses frequently asked questions about CRL stock and offers investment guidance.
Charles River (CRL) Deepens Lilly AI Partnership: What Does TuneLab Access Mean for Its Moat?
Charles River Laboratories (CRL) recently announced a collaboration with Eli Lilly's TuneLab, an AI/ML-driven drug discovery platform, to provide nonclinical testing services. This partnership integrates Charles River into an AI-enabled ecosystem, potentially enhancing its role in preclinical research, especially in data-rich areas like cell and gene therapies. The move aims to offset slower revenue growth and address the emerging risk posed by the accelerated adoption of non-animal testing methods.
Charles River (CRL) Deepens Lilly AI Partnership: What Does TuneLab Access Mean for Its Moat?
Charles River Laboratories (CRL) has deepened its partnership with Eli Lilly's TuneLab, providing nonclinical testing services to AI/ML-driven drug discovery companies using the platform. This collaboration integrates CRL into an AI-enabled ecosystem, potentially enhancing its role in preclinical research and addressing the shift towards data-rich modalities. While this could offset slower revenue growth, investors should consider the risk posed by the accelerated adoption of non-animal testing methods.
Revvity Jumps 6.8% Amid Sector-Wide Rally
Revvity, Inc. saw its stock surge by 6.8% on Wednesday, reaching $106.66, as part of a broad sector-wide rally in the diagnostics and research industry. This increase, alongside similar gains experienced by peers like Illumina and Charles River Laboratories, suggests a shift in investor sentiment toward the entire sector rather than company-specific news. Investors are now watching to see if this rally indicates improved fundamentals across the space or is merely a short-term technical bounce.
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Charles River Laboratories International Inc. (CRL) saw its stock rally by 8.31% to $202.10, outperforming a mixed market session where the Dow Jones Industrial Average rose and the S&P 500 Index fell. This marks the second consecutive day of gains for the company's stock.
Regencell Bioscience stock hits 52-week low at 9.32 USD
Regencell Bioscience (RGC) stock has dropped to a new 52-week low of $9.32, marking a significant downturn with a 53.43% decrease over the past year. This decline follows a 25% weekly drop and a 55% plunge over six months, with InvestingPro analysis suggesting the stock is overvalued and its financial health is "WEAK." The company recently announced a $20 million direct offering of ordinary shares and changed its independent auditing firm.
Charles River Laboratories International Jumps 8.1% in Broad Rally
Charles River Laboratories International (CRL) saw an 8.1% surge on Wednesday, closing at $201.74, driven by a broad sector-wide rally in diagnostics and research companies. This strong performance, outpacing several peers, suggests a reassessment of value in the sector by investors, rather than a response to company-specific news. The synchronized gains among multiple comparable companies indicate renewed investor appetite for the industry, prompting questions about the sustainability of this shift.
2x Valuation Gap: BIO vs. CRL — Who’s Wrong?
This article analyzes the significant valuation gap between Bio-Rad Laboratories (BIO) and Charles River Laboratories (CRL), two life sciences tools companies. While BIO trades at nearly twice the forward earnings multiple of CRL, the author argues that CRL appears to be the better investment due to its positive earnings trajectory and ongoing restructuring efforts, in contrast to BIO's headwinds and less impressive underlying earnings quality. The article concludes that given the 2x valuation discrepancy, Charles River is likely the mispriced and more favorable bet.
Charles River Laboratories consensus in focus, shares under Wall Street scrutiny
Analysts on Wall Street are divided on Charles River Laboratories, as the company's shares show modest year-on-year gains on the NYSE. The consensus is shaped by valuation, the earnings outlook, and comparisons with peers like Labcorp Holding. Despite strong Q1 2026 earnings and an upgrade from Morgan Stanley due to improved biopharma funding, the stock has experienced a volatile 2026 trading pattern.
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Charles River Laboratories International Inc. (CRL) stock increased by 2.78% to $186.60 on a day when the broader market, including the S&P 500 Index and Dow Jones Industrial Average, experienced declines. Despite the gain, the stock remains 18.47% below its 52-week high.
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?
This article compares Bio-Rad Laboratories and Charles River Laboratories International as potential investment opportunities in 2026, weighing their business models, financial performance, risk profiles, and valuations. While both companies are retooling for growth, the author concludes that Charles River Laboratories is the better buy due due to its progress in optimizing its business and its cheaper valuation based on future earnings estimates.
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors
Shares of Charles River Laboratories International Inc. (CRL) fell 1.86% on Monday, closing at $181.56, while the broader market showed mixed performance. The stock underperformed competitors, with the Dow Jones Industrial Average rising and the S&P 500 Index falling. The company's stock is currently 20.67% below its 52-week high reached in January.
